Anti-infectives and the Lung ERS Monograph
- 442 Glossop Road, Sheffield, S10 2PX, UK European Respiratory Society 2017
- 336 pages
- Volume 75 of ERS Monograph .
Contents:
an overview
mechanisms and epidemiology
dosing therapeutic drug monitoring and continuous infusions
Chapter 4 Inhaled antibiotics in chronic airway infections
Chapter 5 Inhaled antibiotics in critical care
Chapter 6 Identifying patients with pneumonia due to MDR organisms coming from the community
Chapter 7 Antibiotic stewardship in the community
Chapter 8 Antibiotic stewardship in the hospital setting
a tripleedged sword
Chapter 13 Treatment options for MDR and XDRTB
Chapter 14 Perspectives on antibiotic treatment of NTM pulmonary disease
Chapter 15 Antibiotics for pleural infections
Chapter 16 Antibiotics in interstitial lung diseases
Chapter 17 Insights into antibiotic use in children with CAP
New Drugs for Bad Bugs and beyond
Chapter 19 Combination antibiotic therapy and synergy in HAP and VAP
Chapter 9 Antibiotic in acute exacerbation of asthma and COPD
to whom when and how?
why what when and to whom?
Blank page
Other titles in the series
Pulmonary infections are a major cause of morbidity and mortality worldwide. Adequate and timely treatment of these infections is therefore of vital importance, especially when considering the emerging problem of antimicrobial resistance. This Monograph provides a comprehensive up-to-date overview of the use of anti-infectives in lung diseases, with chapters covering community- and hospital-acquired pneumonia, exacerbations of asthma and chronic obstructive pulmonary disease, tuberculosis and nontuberculous mycobacteria pulmonary disease, pleural infections, and fungal diseases. Other chapters address antibiotic stewardship in the community and hospital settings, and the use of antibiotics in specific patient groups (e.g. critically ill and paediatric patients). Mechanisms of action and resistance, diagnostic approaches, therapeutic options (e.g. combination therapy, dosing and routes of administration), and the development of new drugs are also discussed.